By Drug Target Review2025-08-07T08:30:48
Researchers at Mount Sinai have mapped how the 5-HT1A serotonin receptor controls brain signalling – finding a hidden lipid ‘co-pilot’ that could lead to the development of more targeted antidepressants.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-03-31T14:05:00Z
2026-03-30T09:54:00Z
2025-05-14T14:30:00
Sponsored by Abzena
2025-06-11T14:00:00
Sponsored by Eurofins Discovery
2024-01-10T08:23:16
Sponsored by BellBrook Labs
2023-02-07T15:25:20
Sponsored by Bio-Techne
2023-02-03T13:56:13
Sponsored by Leica Microsystems
2023-09-27T13:56:39
Sponsored by Euretos
Site powered by Webvision Cloud